Effects of ART Simplification on Inflammatory Markers in CoRis (AIR)
NCT03501719 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 177
Last updated 2025-03-17
Summary
The effects of the number of drugs included in antiretroviral therapy (ART) regimens of inflammatory markers remains undefined. We will evaluated in participants in the Spanish AIDS Research Network, whether triple ART, dual ART or monotherapy affect differentially the dynamics of inflammatory markers.
Conditions
Interventions
- DRUG
-
Number of drugs in the ART regimen
Triple therapy vs. dual therapy vs. monotherapy
Sponsors & Collaborators
-
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-03-01
- Primary Completion
- 2022-03-01
- Completion
- 2022-03-01
- FDA Drug
- Yes
Countries
- Spain
Study Locations
More Related Trials
-
Saquinavir/Ritonavir in Single Therapy as Maintenance Treatment
NCT00379405 ·Status: COMPLETED ·Phase: PHASE4
-
Ambispective Cohort Study to Evaluate the Efficacy, Safety, and Tolerance of an Antiretroviral Regimen With Doravirine
NCT05140603 ·Status: UNKNOWN
-
HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults
NCT00450580 ·Status: COMPLETED ·Phase: PHASE3
-
Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients
NCT01702090 ·Status: COMPLETED ·Phase: PHASE4
-
DRV/r + RPV QD: Efficacy and Toxicity Reduction
NCT01792570 ·Status: COMPLETED ·Phase: PHASE3
-
Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients
NCT01274780 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir
NCT00458302 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment
NCT00004581 ·Status: COMPLETED ·Phase: PHASE3
-
Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir
NCT00120393 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up
NCT07138144 ·Status: RECRUITING ·Phase: PHASE4
-
A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen
NCT00135395 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 Hours
NCT00607958 ·Status: COMPLETED ·Phase: PHASE4
-
Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection
NCT00440947 ·Status: COMPLETED ·Phase: PHASE3
-
An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.
NCT00933205 ·Status: APPROVED_FOR_MARKETING
-
Long-Term Data Collection From Participants in Adult AIDS Clinical Trials
NCT00001137 ·Status: COMPLETED
-
Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART
NCT00038532 ·Status: COMPLETED ·Phase: PHASE2
-
ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects
NCT00004578 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Antiretroviral Treatment Simplification Study With Efavirenz + Abacavir + 3TC Once Daily
NCT00314626 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)
NCT02652260 ·Status: COMPLETED ·Phase: PHASE2
-
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
NCT01605084 ·Status: WITHDRAWN ·Phase: PHASE3
-
Pilot Study of a Raltegravir Based NRTI Sparing Regimen
NCT00814879 ·Status: COMPLETED ·Phase: NA
-
Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine
NCT02284035 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
NCT00002364 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)
NCT01910402 ·Status: COMPLETED ·Phase: PHASE3
-
Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)
NCT00054717 ·Status: COMPLETED ·Phase: PHASE3